Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163074 | 0.84 | L3MBTL1 (0.50) | HPGDDAOCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL12169429 | 0.81 | HPGD (0.59) | HPGD | |
| SCHEMBL4176930 | 0.81 | TYMP (0.48) | HPGDDAOKMT2AMEN1CYP1A2 | |
| SCHEMBL4172709 | 0.80 | HPGD (0.67) | HPGDDAOKMT2AMEN1CYP1A2 | |
| SCHEMBL7839293 | 0.78 | TYMP (0.52) | HPGDDAOKMT2AMEN1 | |
| SCHEMBL28245641 | 0.77 | DAO (0.44) | HPGDDAOKMT2AMEN1 | |
| SCHEMBL4156367 | 0.75 | KDM4E (0.43) | HPGDDAOKMT2AMEN1BLM | |
| SCHEMBL4167785 | 0.75 | KDM4E (0.48) | HPGDKMT2AMEN1CYP1A2BLM | |
| SCHEMBL5347308 | 0.72 | KMT2A (0.44) | HPGDDAOKMT2AMEN1CYP1A2 | |
| SCHEMBL7834032 | 0.71 | SMN1; SMN2 (0.64) | HPGDDAOKMT2AMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| WO-2007122634-A2 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122634-A2 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | TK1, LCK, FYN | HPGD 1010/4885DAO 1019/4885KMT2A 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.